EVOLVE-MI: EVOLocumab Very Early after Myocardial InfarctionEVOLVE-MI
Study Details
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction [STEMI]).
Protocol Summary
Total (first and subsequent) composite of myocardial infarction, ischemic stroke, any arterial revascularization procedure, and all-cause death
Timeframe: From Baseline to End of Study (Approximately 3.5 Years)
Percentage Change From Baseline in LDL-C
Timeframe: From Baseline to Week 12
Percentage Change From Baseline in LDL-C
Timeframe: From Baseline to Week 52
Total (first and subsequent) composite of myocardial infarction, ischemic stroke, any arterial revascularization procedure, and cardiovascular death
Timeframe: From Baseline to End of Study (Approximately 3.5 Years)
Time to the First Occurrence of the Composite of Myocardial Infarction, Ischemic Stroke, any Arterial Revascularization Procedure, and All-Cause Death
Timeframe: From Baseline to End of Study (Approximately 3.5 Years)
Total Myocardial Infarctions Events
Timeframe: From Baseline to End of Study (Approximately 3.5 Years)
Total Arterial Revascularization Procedures
Timeframe: From Baseline to End of Study (Approximately 3.5 Years)
Total Ischemia-driven Coronary Revascularization Procedures
Timeframe: From Baseline to End of Study (Approximately 3.5 Years)
Total Ischemic Strokes
Timeframe: From Baseline to End of Study (Approximately 3.5 Years)
Time to Cardiovascular Death
Timeframe: From Baseline to End of Study (Approximately 3.5 Years)
Time to All-Cause Death
Timeframe: From Baseline to End of Study (Approximately 3.5 Years)